UBS Group’s Orexigen Therapeutics, Inc. OREX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2018
Q2 | – | Sell |
-11,155
| Closed | -$3K | – | 7527 |
|
|
2018
Q1 | $3K | Buy |
11,155
+8,505
| +321% | +$2.29K | ﹤0.01% | 6605 |
|
|
2017
Q4 | $3K | Sell |
2,650
-60
| -2% | -$68 | ﹤0.01% | 6608 |
|
|
2017
Q3 | $6K | Sell |
2,710
-2,419
| -47% | -$5.36K | ﹤0.01% | 6271 |
|
|
2017
Q2 | $15K | Buy |
5,129
+46
| +0.9% | +$135 | ﹤0.01% | 5585 |
|
|
2017
Q1 | $17K | Buy |
5,083
+1,373
| +37% | +$4.59K | ﹤0.01% | 5375 |
|
|
2016
Q4 | $6K | Buy |
3,710
+100
| +3% | +$162 | ﹤0.01% | 6238 |
|
|
2016
Q3 | $12K | Buy |
3,610
+3,180
| +740% | +$10.6K | ﹤0.01% | 5788 |
|
|
2016
Q2 | $2K | Sell |
430
-190
| -31% | -$884 | ﹤0.01% | 6584 |
|
|
2016
Q1 | $3K | Hold |
620
| – | – | ﹤0.01% | 6397 |
|
|
2015
Q4 | $11K | Sell |
620
-3,183
| -84% | -$56.5K | ﹤0.01% | 5980 |
|
|
2015
Q3 | $80K | Buy |
3,803
+2,887
| +315% | +$60.7K | ﹤0.01% | 4363 |
|
|
2015
Q2 | $45K | Sell |
916
-330
| -26% | -$16.2K | ﹤0.01% | 4852 |
|
|
2015
Q1 | $98K | Buy |
1,246
+371
| +42% | +$29.2K | ﹤0.01% | 4204 |
|
|
2014
Q4 | $53K | Buy |
+875
| New | +$53K | ﹤0.01% | 4686 |
|